Incyte (INCY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY)

INCY 106.00

+0.8%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (3003)	12/9/2013 12:56:11 PM
From: scaram(o)uche	Read Replies (1) of 3202

finance.yahoo.com Jakafi® (ruxolitinib) Continues to Show Improved Overall Survival for Patients with Myelofibrosis in Further Analyses of Phase III Data Presented at 2013 ASH • Data from multiple presentations, including three-year follow-up analysis from COMFORT-I and a pooled analysis of the two COMFORT trials, suggest that patients treated with Jakafi maintained reductions in spleen volume and had improved survival over placebo and best available therapy • A separate retrospective analysis suggests that Jakafi treatment may reduce the risk of death by approximately 50 percent compared to conventional treatments • An exploratory analysis of data collected over five years in the ongoing Phase II trial offers evidence that Jakafi may stabilize or improve bone marrow fibrosis in patients with myelofibrosis snip

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next